Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L H Patterson

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2004
Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approachC S Lane, S Nisar, W J Griffiths, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2007
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I studyW P Steward, M Middleton, A Benghiat, et al.
Cancer Gene Therapy|January 18, 2006
Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4NA Yakkundi, V McErlane, M Murray, et al.
British Journal of Cancer|April 26, 2000
Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamineO P Friery, R Gallagher, M M Murray, et al.
Journal of Proteome Research|March 16, 2012
Characterization of changes in the proteome in different regions of 3D multicell tumor spheroidsK M McMahon, M Volpato, H Y Chi, et al.
Cytometry|August 5, 2000
Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopyP J Smith, N Blunt, M Wiltshire, et al.
British Journal of Cancer|March 5, 2002
The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1G A Potter, L H Patterson, E Wanogho, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2004
Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approachC S Lane, S Nisar, W J Griffiths, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2007
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I studyW P Steward, M Middleton, A Benghiat, et al.
Cancer Gene Therapy|January 18, 2006
Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4NA Yakkundi, V McErlane, M Murray, et al.
British Journal of Cancer|April 26, 2000
Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamineO P Friery, R Gallagher, M M Murray, et al.
Journal of Proteome Research|March 16, 2012
Characterization of changes in the proteome in different regions of 3D multicell tumor spheroidsK M McMahon, M Volpato, H Y Chi, et al.
Cytometry|August 5, 2000
Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopyP J Smith, N Blunt, M Wiltshire, et al.
British Journal of Cancer|March 5, 2002
The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1G A Potter, L H Patterson, E Wanogho, et al.
Pageof 7